Treatment of multiple myeloma with deoxycoformycin

Abo T, Yamaguchi T, Shimizu F, Kumagai K (1976) Studies of surface immunoglobins on human B lymphocytes. J Immunol 117:1781

Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB (1979) The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med 301:743

Bonnet J, Alexanian R, Salmon S, Bottomley R, Amare M, Haut A, Dixon D (1982) Vincristine, BCNU, doxorubicin and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a southwest oncology group study. Cancer Treat Rep 66:1267

Brox LW, Pollock E, Belch A (1981) Adenosine and deoxyadenosine toxicity in colony assay systems for human T-lymphocytes, B-lymphocytes and granulocytes. Cancer Chemother Pharmacol 9:49

Carson DA, Wasson DB, Lakow E, Kamatani N (1982) Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc Natl Acad Sci USA 79:3848

Fox IH, Kelley WN (1978) The role of adenosine and 2?-deoxy-adenosine in mammalian cells. Annu Rev Biochem 47:655

Giblett ER, Anderson F, Cohen B, Pollara B, Meuwissen HJ (1972) Adenosine deaminase deficiency in two patients with severely impaired immunity. Lancet 2:1067

Henderson JF, Scott FW (1980) Inhibition of animal and invertebrate cell growth by naturally occurring purine bases and ribonucleosides. Pharmacol Therapy [A] 8:539

Huang AT, Logue GL, Engelbracht HL (1976) Two biochemical markers in lymphocyte subpopulations. Br J Haematol 34:631

Hunting D, Hordern J, Henderson JF (1981) Quantitative analysis of purine and pyrimidine metabolism in Chinese hamster ovary cells. Can J Biochem 59:838

Kefford RF, Fox RM (1982) Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes. Br J Haematol 50:627

Kefford RF, Fox RM (1983) Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors. Cancer Chemother Pharmacol 10:73

Koller CA, Mitchell BS (1981) 2?-Deoxycoformycin toxicity correlates with red cell dATP/ATP ratios. Proc Am Assoc Cancer Res 22:220

Kyle RA, Pajak TF, Henderson ES, Nawabi IS, Brunner K, Henry PH, McIntyre OR, Holland JF (1982) Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, BCNU and prednisone. Cancer Treat Rep 66:451

Lowe JK, Gowans B, Brox L (1977) Deoxyadenosine metabolism and toxicity in cultured L5178Y cells. Cancer Res 37:3013

Macdermott RP, Tritsch GL, Formeister JF (1980) Adenosine deaminase and nucleoside phosphorylase activities in normal human blood mononuclear cell subpopulations. Clin Exp Immunol 42:303

Nishida Y, Okudaira K, Tanimoto K, Akaota I (1980) The differences in purine metabolism between T and B lymphocytes. Exp Hematol 8:593

Poplack DG, Sallan SE, Rivera G, Holcenberg J, Murphy SB, Blatt J, Lipton JM, Venner P, Glaubiger DL, Ungerleider R, Johns D (1981) Phase I study of 2?-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res 41:3343

Preiksaitis JK, Lank B, Ng PK, Brox L, LePage GA, Tyrrell DLJ (1981) Effect of liver disease on pharmacokinetics and toxicity of 9-?-D-arabinofuranosyladenine-5?-phosphate. J Infect Dis 144:358

Prentice HG, Lee N, Blacklock H, Smyth JF, Russell NH, Ganeshaguru K, Piga A, Hoffbrand AV (1981) Therapeutic selectivity of and prediction of response to 2?-deoxycoformycin in acute leukemia. Lancet 2:1250

Smyth JF (1979) Selective treatment of lymphoids malignancy with adenosine deaminase inhibitors. In: Enzyme defects and immune dysfunction. Excerpta Medica, Amsterdam, p 263 (Ciba Foundation symposium no 68)

Tung R, Silber R, Qualiata F, Conklyn M, Gottesman J, Hirschhorn R (1976) Adenosine deaminase activity in chronic lymphocytic leukemia. J Clin Invest 57:756

Weiner MS, Bianco C, Nussenweig V (1973) Enhanced binding of neuraminidase-treated sheep erythrocytes to human T-lymphocytes. Blood 42:939